This seems pretty straight forward to me...
https://blogs.sciencemag.org/pipelin...enough-already
"96,032 patients were registered in these hospitals with the coronavirus during the study period (December 20, 2019 to April 14, 2020); this is a large data set. The mean age of the patients was just under 54 years, 54/46 male/female. 14,888 of them were in the treatment sets defined above: 1868 got straight chloroquine, 3783 got chloroquine with a macrolide, 3016 received hydroxychloroquine by itself, and another 6221 got HCQ with a macrolide). That leaves 81,144 patients as a control group getting other standard of care. Let’s note at the start that the authors controlled for a number of confounding factors (such as age, sex, race or ethnicity, body-mass index, cardiovascular disease and risk factors, diabetes, lung disease, smoking, immunosuppressed condition, and overall disease severity). How’d it go?"
"Judge for yourself. The mortality in the control group was 9.3%. The mortality in the chloroquine group was 16.4%. The mortality in the chloroquine plus macrolide group was 22.2%. The mortality in the hydroxychloroquine group was 18%. And the mortality in the hydroxychloroquine plus macrolide group was 23.8%."
"Let’s look at cardiac arrhythmia. The 0.3% of the control group developed new arrhythmias during their hospitalization. But 4.3% of the chloroquine treatment group did. And 6.5% of the chloroquine plus macrolide group. As did 6.1% of the hydroxychloroquine group. And 8.1% of the hydroxychlorquine plus macrolide group."
If anyone reads that and wants to take that, more power to you I guess.